Related Experiment Video
Updated: Mar 1, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease
Soumaya Allouch1, Shankar Munusamy1,2
1College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar.
Background:
Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMPactivated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD.
Objective:
The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.
Insights
AMP-activated protein kinase (AMPK) deficiency contributes to chronic kidney disease (CKD) by disrupting cellular balance. AMPK activation, potentially via metformin, shows promise for preventing and treating CKD.
Area of Science:
- Nephrology
- Molecular Biology
- Cellular Biology
Background:
- Chronic kidney disease (CKD) affects millions globally, being a leading cause of death.
- AMP-activated protein kinase (AMPK) is crucial for cellular energy balance.
- CKD pathogenesis involves impaired AMPK activity, autophagy, mTOR, and ER stress, promoting kidney damage.
Purpose of the Study:
- To review the nephroprotective effects of AMPK.
- To explore AMPK as a therapeutic target for CKD prevention and treatment.
Main Methods:
- Literature review focusing on AMPK's role in CKD.
- Analysis of experimental and clinical evidence on AMPK activators.
Main Results:
- AMPK modulates key pathways implicated in CKD, including epithelial-to-mesenchymal transition and apoptosis.
- Pharmacological AMPK activators, like metformin, demonstrate renoprotective effects in studies.
- Metformin has shown potential to improve clinical outcomes in CKD patients.
Conclusions:
- AMPK plays a critical role in maintaining kidney health.
- Targeting AMPK offers a promising therapeutic strategy for managing CKD.
More Related Videos
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
cAMP-dependent Protein Kinase Pathways
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management